Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Adamas Pharmaceuticals Inc.

Headquarters: Emeryville, CA, United States of America
Website: N/A
Year Founded: 2000
Status: Acquired

BioCentury | Oct 10, 2023
Management Tracks

Amgen veteran Lenz named head of R&D at Neumora

Plus: Eaton leaving Editas as CTO, CBO and updates from Poseida, Zevra, Pheon, Lexicon and more
BioCentury | Jun 13, 2023
Management Tracks

Patni becomes chief of R&D at Reata

Plus: Reilly named CEO at Damona, and updates from Akebia, Generate, Jasper and more
BioCentury | Sep 29, 2022
Management Tracks

Kevin Bunker promoted to CSO at Zentalis

Plus Fonck becomes partner at Pureos, and updates from 4D Molecular, Gandeeva, Code and more
BioCentury | Sep 21, 2022
Management Tracks

New CEOs at Scholar Rock, Neuway, NeuVasQ and ProLynx

Plus Serono’s Maria Rivas joins Pfizer, and updates from 
BioCentury | Aug 4, 2022
Management Tracks

Sanofi’s Lih-Ling Lin joins PharmaEssentia as CSO

Plus Hunder becomes CMO at ProfoundBio, and updates from Nurix, Sanofi and Nucleai
BioCentury | Apr 20, 2022
Management Tracks

New CEOs at eGenesis, Fore and Cerevance

Plus Ramanan joins Turnstone as CFO, updates from Camp4, ImmPact, Akoya and more
BioCentury | Oct 12, 2021
Product Development

Oct. 11 Quick Takes: Supernus diversifies CNS portfolio with Adamas acquisition

Plus: Idorsia’s miss, Evotec, Protagonist, Enzyvant and Chance
BioCentury | Feb 2, 2021
Product Development

Feb. 2 Quick Takes: Immunovant tumbles as it pauses trial; plus BMS, Legend-J&J, Arcutis, Prothena, VBI, Travere, Concert and Adamas

Immunovant Inc. (NASDAQ:IMVT) lost 42% to $25.08 on Tuesday after announcing it was pausing trials of anti-FCRN mAb IMVT-1401 (batoclimab) due to elevated total cholesterol and LDL signals in the
BioCentury | Apr 6, 2018
Finance

Smid-cap smorgasbord

Buysiders like 2Q cancer catalysts, rare diseases and small- to mid-cap milestones
Items per page:
1 - 10 of 65
Help Center
Username
Request a Demo
Request Training
Ask a Question